|
1
|
Long E and Beales IL: The role of obesity
in oesophageal cancer development. Therap Adv Gastroenterol.
7:247–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fischer OM, Hart S, Gschwind A and Ullrich
A: EGFR signal transactivation in cancer cells. Biochem Soc Trans.
31:1203–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu CL, Meyer DJ, Campbell GS, Larner AC,
Carter-Su C, Schwartz J and Jove R: Enhanced DNA-binding activity
of a Stat3-related protein in cells transformed by the Src
oncoprotein. Science. 269:81–83. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams GP and Weiner LM: Monoclonal
antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang YN, Yamaguchi H, Hsu JM and Hung MC:
Nuclear trafficking of the epidermal growth factor receptor family
membrane proteins. Oncogene. 29:3997–4006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miqueli Diaz A, Blanco R, Garcia B, Badia
T, Batista AE, Alonso R and Montero E: Biological activity in vitro
of anti-epidermal growth factor receptor monoclonal antibodies with
different affinities. Hybridoma (Larchmt). 26:423–431. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rojo F, Gracias E, Villena N, Cruz T,
Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N,
et al: Pharmacodynamic trial of nimotuzumab in unresectable
squamous cell carcinoma of the head and neck: a SENDO Foundation
study. Clin Cancer Res. 16:2474–2482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bebb G, Smith C, Rorke S, Boland W,
Nicacio L, Sukhoo R and Brade A: Phase I clinical trial of the
anti-EGFR monoclonal antibody nimotuzumab with concurrent external
thoracic radiotherapy in Canadian patients diagnosed with stage
IIb, III or IV non-small cell lung cancer unsuitable for radical
therapy. Cancer Chemother Pharmacol. 67:837–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandey A, Noronha V, Joshi A, Tongaonkar
H, Bakshi G and Prabhash K: Resistant metastatic penile carcinoma
and response to biochemotherapy with paclitaxel and epidermal
growth factor receptor monoclonal antibody, nimotuzumab. Indian J
Med Paediatr Oncol. 34:24–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garrido G, Tikhomirov IA, Rabasa A, Yang
E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS and Pérez
R: Bivalent binding by intermediate affinity of nimotuzumab a
contribution to explain antibody clinical profile. Cancer Biol
Ther. 11:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu Y, Li X, Liang K, Luwor R, Siddik ZH,
Mills GB, Mendelsohn J and Fan Z: Epidermal growth factor receptor
(EGFR) ubiquitination as a mechanism of acquired resistance
escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Cancer Res. 67:8240–8247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liccardi G, Hartley JA and Hochhauser D:
EGFR nuclear translocation modulates DNA repair following cisplatin
and ionizing radiation treatment. Cancer Res. 71:1103–1114. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dittmann K, Mayer C, Fehrenbacher B,
Schaller M, Kehlbach R and Rodemann HP: Nuclear EGFR shuttling
induced by ionizing radiation is regulated by phosphorylation at
residue Thr654. FEBS Lett. 584:3878–3884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wheeler DL, Huang S, Kruser TJ,
Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and
Harari PM: Mechanisms of acquired resistance to cetuximab, role of
HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loupakis F, Pollina L, Stasi I, Ruzzo A,
Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E,
et al: PTEN expression and KRAS mutations on primary tumors and
metastases in the prediction of benefit from cetuximab plus
irinotecan for patients with metastatic colorectal cancer. J Clin
Oncol. 27:2622–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim SM, Kim JS, Kim JH, Yun CO, Kim EM,
Kim HK, Solca F, Choi SY and Cho BC: Acquired resistance to
cetuximab is mediated by increased PTEN instability and leads
cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett.
296:150–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
